(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



i 1868, bilitali o bilita koji 6191. 6611. 1841. ili o 6119. 6131. 6441. ili o 6119. ili o 6119. ili o 6119. ili

(43) International Publication Date 15 January 2004 (15.01.2004)

(10) International Publication Number WO 2004/005281 A1

(51) International Patent Classification7: 405/14, A61K 31/506, A61P 35/00

C07D 401/14,

(21) International Application Number:

PCT/EP2003/007198

(22) International Filing Date:

4 July 2003 (04.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0215676.8

5 July 2002 (05.07.2002) GB

0229893.3

20 December 2002 (20.12.2002)

- (71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4002 Basel (CH).
- (71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BREITENSTEIN, Werner [CH/CH]; St. Galler-Ring 179, CH-4054 Basel (CH). FURET, Pascal [FR/FR]; Rue du Riegelsbourg, 24, F-68800 Thann (FR). JACOB, Sandra [AU/FR]; Impasse des Lilas 3, F-68800 Thann (FR). MANLEY, Paul, William [GB/CH]; Bruggweg 12, CH-4144 Arlesheim (CH).


- (74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.
- (84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: INHIBITORS OF TYROSINE KINASES



(57) Abstract: The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/14 C07D405/14 A61P35/00 A61K31/506

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\begin{array}{ccc} \text{MinImum documentation searched (classification system followed by classification symbols)} \\ \text{IPC 7} & \text{C07D} \\ \end{array}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

K	ZIMMERMANN J ET AL: "Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 2, 21 January 1997 (1997-01-21), pages 187-192, XP004135990 ISSN: 0960-894X examples 17,24; table 1	1-14
Y	the whole document/	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.		
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed 	 "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family 		
Date of the actual completion of the international search	Date of mailing of the international search report		
1 December 2003	09/12/2003		
Name and mailing address of the ISA	Authorized officer		
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Timmermans, M		



Int Shal Application No PC17 EP 03/07198

		PC17EP 03/0/198						
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT								
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.						
Y	ZIMMERMANN J ET AL: "Phenylamino-pyrimidine (PAP) - derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 11, 4 June 1996 (1996-06-04), pages 1221-1226, XP004134858 ISSN: 0960-894X examples 3,11; table 1	1-14						
Y	EP 0 588 762 A (CIBA GEIGY AG) 23 March 1994 (1994-03-23) page 3, line 52 - line 56; claim 1	1-14						
Y	PAUL R ET AL: "Preparation of substituted N-phenyl-4-aryl-2-pyrimidinamines as mediator release inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 36, no. 19, 17 September 1993 (1993-09-17), pages 2716-2725, XP002134022 ISSN: 0022-2623 examples 2-7,2-22; table II	1-14						
Y	WO 95 09853 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 (1995-04-13) the whole document	1-14						

INTERNATIONAL SEARCH REPORT

ion on patent family members

Int, President Application No PCT/CP 03/07198

				101721	05/0/150
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0588762	Α	23-03-1994	EP	0588762 A1	23-03-1994
E1 0300702	^	20 00 1001	JΡ	6184116 A	05-07-1994
			ÜS	5516775 A	14-05-1996
WO 9509853		13-04-1995	 AT	208772 T	15-11-2001
WO 2002000	•		AU	691834 B2	28-05-1998
			AU	7697794 A	01-05-1995
			CA	2148928 A1	13-04-1995
			CN	1115982 A ,B	31-01-1996
			CZ	9501722 A3	13-03-1996
			DE	69429078 D1	20-12-2001
			DE	69429078 T2	11-07-2002
			DK	672041 T3	25-02-2002
			WO	9509853 A1	13-04-1995
			EP	0672041 A1	20-09-1995
			ES	2167377 T3	16-05-2002
			FI	952607 A	29-05-1995
			HU	72609 A2	28-05-1996
			IL	111077 A	28-10-1999
			JP	2983636 B2	29-11-1999
			JP	8504215 T	07-05-1996
			NO	952132 A	30-05-1995
			NZ	273617 A	26-11-1996
			PL	309225 A1	02-10-1995
			PT	672041 T	29-04-2002
			RU	2135491 C1	27-08-1999
			SG	45183 A1	16-01-1998
			SI	672041 T1	30-04-2002
			TW	378208 B	01-01-2000
•			US	5728708 A	17-03-1998
			ZA	9407657 A	03-04-1995